Deupirfenidone ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2

85. 特発性間質性肺炎

---

臨床試験数 : 627 /  薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-006820-41-GR (EUCTR)	23/12/2022	16/09/2022	A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).	Idiopathic Pulmonary Fibrosis (IPF);Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	Product Name: deupirfenidone Product Code: LYT-100 INN or Proposed INN: deupirfenidone Other descriptive name: Pirfenidone, deuterated Product Name: pirfenidone INN or Proposed INN: Pirfenidone Other descriptive name: Pirfenidone	PureTech LYT 100, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	240	Phase 2	Serbia;United States;Czechia;Taiwan;Greece;Thailand;Chile;Colombia;India;Mexico;Argentina;Malaysia;Poland;Romania;Georgia;Korea, Republic of
2	NCT05321420 (ClinicalTrials.gov)	July 29, 2022	2/4/2022	LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis	Drug: Placebo;Drug: Pirfenidone;Drug: Deupirfenidone	PureTech	NULL	Recruiting	40 Years	N/A	All	240	Phase 2	United States;Argentina;Georgia;Greece;India;Malaysia;Romania;Thailand